Associated Papers
Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.
Zhang T et al.
Peerj, 2024
39465171 (PubMed )
Supplement: peerj-12-18360-s002.7z › drug-metabolizing_enzymes_and_transporter__DMET__microarray › markerlist.xlsx › markerlist.TXT
The substrate and inhibitor binding mechanism of polyspecific transporter OAT1 revealed by high-resolution cryo-EM.
Dou T et al.
Nature Structural & Molecular Biology, 2023
Substrate binding and lipid-mediated allostery in the human organic anion transporter 1 at the atomic-scale.
Janaszkiewicz A et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 2023
Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform.
Kim B et al.
Translational and Clinical Pharmacology, 2021
34621706 (PubMed )
Supplement: tcp-29-135-s001.xls › tcp-29-135-s001
Genetic Diversity in Drug Transporters: Impact in African Populations.
Rajman I et al.
Clinical and Translational Science, 2020
Genetic Heterogeneity of SLC22 Family of Transporters in Drug Disposition.
Lozano E et al.
Journal of Personalized Medicine, 2018
Screening of genetic variations of SLC15A2, SLC22A1, SLC22A2 and SLC22A6 genes.
Cheong HS et al.
Journal of Human Genetics, 2011
Identification of genetic polymorphisms of human OAT1 and OAT2 genes and their relationship to hOAT2 expression in human liver.
Shin HJ et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry, 2010
Hepatocyte nuclear factor-4{alpha} regulates the human organic anion transporter 1 gene in the kidney.
Ogasawara K et al.
American Journal of Physiology. Renal Physiology, 2007
Functional analysis of polymorphisms in the organic anion transporter, SLC22A6 (OAT1).
Fujita T et al.
Pharmacogenetics and Genomics, 2005
Select a paper to view details